In yesterday’s Wall Street session, Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares traded at $1.25, down -5.30% from the previous session.
As of this writing, 8 analysts cover Adaptimmune Therapeutics plc (NASDAQ:ADAP). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $2.00, we find $4.00. Given the previous closing price of $1.32, this indicates a potential upside of 203.03 percent. ADAP stock price is now -25.76% away from the 50-day moving average and -26.94% away from the 200-day moving average. The market capitalization of the company currently stands at $190.84M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
There are 3 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $5.17 as their price target over the next twelve months.
With the price target maintained at $5, Guggenheim recently Upgraded its rating from Neutral to Buy for Adaptimmune Therapeutics plc (NASDAQ: ADAP). On November 09, 2022, Mizuho Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $9, while ‘Barclays’ rates the stock as ‘Underweight’.
In other news, Piccina Cintia, Chief Commercial Officer sold 11,890 shares of the company’s stock on Jan 31. The stock was sold for $22,230 at an average price of $1.87. Upon completion of the transaction, the Chief Commercial Officer now directly owns 19,535 shares in the company, valued at $24418.75. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 17, Chief Executive Officer Rawcliffe Adrian sold 10,057 shares of the business’s stock. A total of $18,686 was realized by selling the stock at an average price of $1.86. This leaves the insider owning 13,351 shares of the company worth $16688.75. Insiders disposed of 13,169 shares of company stock worth roughly $16461.25 over the past 1 year. A total of 0.12% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ADAP stock. A new stake in Adaptimmune Therapeutics plc shares was purchased by LAZARD ASSET MANAGEMENT LLC during the first quarter worth $130,000. MARSHALL WACE, LLP invested $118,000 in shares of ADAP during the first quarter. In the first quarter, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP acquired a new stake in Adaptimmune Therapeutics plc valued at approximately $43,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in ADAP for approximately $37,000. QUBE RESEARCH & TECHNOLOGIES LTD purchased a new stake in ADAP valued at around $36,000 in the second quarter. In total, there are 93 active investors with 70.30% ownership of the company’s stock.
Tuesday morning saw Adaptimmune Therapeutics plc (NASDAQ: ADAP) opened at $1.3200. During the past 12 months, Adaptimmune Therapeutics plc has had a low of $1.01 and a high of $2.65. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.00, and a quick ratio of 4.00. The fifty day moving average price for ADAP is $1.6838 and a two-hundred day moving average price translates $1.7108 for the stock.
The latest earnings results from Adaptimmune Therapeutics plc (NASDAQ: ADAP) was released for Dec, 2022. According to the Biotechnology Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.25 by 0.22. This compares to -$0.25 EPS in the same period last year. The company reported revenue of $11.03 million for the quarter, compared to $1.42 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 678.26 percent. For the current quarter, analysts expect ADAP to generate $4.66M in revenue.
Adaptimmune Therapeutics plc(ADAP) Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company’s specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
